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Diabetic kidney disease, or diabetic nephropathy (DN), is a major complication of diabetes and the leading cause of end-
stage renal disease (ESRD) that requires dialysis treatment or kidney transplantation. In addition to the decrease in the
quality of life, DN accounts for a large proportion of the excess mortality associated with type 1 diabetes (T1D). Whereas the
degree of glycemia plays a pivotal role in DN, a subset of individuals with poorly controlled T1D do not develop DN.
Furthermore, strong familial aggregation supports genetic susceptibility to DN. However, the genes and the molecular
mechanisms behind the disease remain poorly understood, and current therapeutic strategies rarely result in reversal of DN.
In the GEnetics of Nephropathy: an International Effort (GENIE) consortium, we have undertaken a meta-analysis of genome-
wide association studies (GWAS) of T1D DN comprising ,2.4 million single nucleotide polymorphisms (SNPs) imputed in
6,691 individuals. After additional genotyping of 41 top ranked SNPs representing 24 independent signals in 5,873
individuals, combined meta-analysis revealed association of two SNPs with ESRD: rs7583877 in the AFF3 gene (P=1.2610
28)
and an intergenic SNP on chromosome 15q26 between the genes RGMA and MCTP2, rs12437854 (P=2.0610
29). Functional
data suggest that AFF3 influences renal tubule fibrosis via the transforming growth factor-beta (TGF-b1) pathway. The
strongest association with DN as a primary phenotype was seen for an intronic SNP in the ERBB4 gene (rs7588550,
P=2.1610
27), a gene with type 2 diabetes DN differential expression and in the same intron as a variant with cis-eQTL
expression of ERBB4. All these detected associations represent new signals in the pathogenesis of DN.
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Introduction
Diabetic kidney disease, or diabetic nephropathy (DN), is the
leading cause of end-stage renal disease (ESRD) worldwide [1]. It
affects approximately 30% of patients with long-standing type 1
and type 2 diabetes [2,3], and confers added risks of cardiovas-
cular disease and mortality. DN is a progressive disorder that is
characterized by proteinuria (abnormal loss of protein from the
blood compartment into the urine) and gradual loss of kidney
function. Early in its course, the kidneys are hypertrophic, and
glomerular filtration is increased. However, with progression over
several years, proteinuria and decline in kidney function set in, and
may result in fibrosis and terminal kidney failure, necessitating
costly renal replacement therapies, such as dialysis and renal
transplantation. While current treatments that decrease protein-
uria will moderately abate DN progression, recent studies show
that even with delivery of optimal care, high risks of cardiovascular
disease, ESRD and mortality persist [4,5]. Therefore, discovery of
genetic factors that influence development and susceptibility to
DN is a critical step towards the identification of novel
pathophysiologic mechanisms that may be targeted for interven-
tions to improve the adverse clinical outcomes in diabetic patients.
GWAS on Diabetic Nephropathy
PLOS Genetics | www.plosgenetics.org 2 September 2012 | Volume 8 | Issue 9 | e1002921Whereas the degree of glycemia plays a pivotal role in DN, a
subset of individuals with poorly controlled type 1 diabetes (T1D)
do not develop DN. Furthermore, strong familial aggregation
supports genetic susceptibility to DN. The sibling risk of DN has
been estimated to be 2.3-fold [6]. While prior studies of individuals
with T1D have reported on the possible existence of genetic
associations for DN, results have been inconclusive. In GENIE, we
leveraged three existing collections for T1D nephropathy (All
Ireland Warren 3 Genetics of Kidneys in Diabetes UK Collection
[UK-ROI], Finnish Diabetic Nephropathy Study [FinnDiane],
and Genetics of Kidneys in Diabetes US Study [GoKinD US])
comprising 6,691 individuals to perform the most comprehensive
and well powered DN susceptibility genome-wide association
study (GWAS) and meta-analysis to date, with the aim to identify
genetic markers associated with DN by meta-analyzing indepen-
dent GWAS, imputed to HapMap CEU II (Table 1, Figure 1). As
a result, we here present two new loci associated with ESRD and a
locus suggestively associated with DN.
Results/Discussion
The primary phenotype of interest was DN, defined by the
presence of persistent macroalbuminuria or ESRD in individuals
aged over 18 who had T1D for at least 10-year duration. Controls
were defined as individuals with T1D for at least 15 years but
without any clinical evidence of kidney disease (see Methods for
more detailed definitions). Meta-analysis of the DN results from
each cohort resulted in five independent signals with P,10
25
(Table S1, Figure S1A). In a parallel analysis of ESRD versus non-
ESRD (n cases=1,399, n controls=5,253; referred to as ‘‘ESRD’’
analysis throughout the manuscript, unless otherwise stated), SNP
rs7583877 on chromosome 2q11.2-q12 achieved genome-wide
significance (P=4.8610
29), primarily driven by FinnDiane and
the UK-ROI samples, along with six other independent signals
reaching P,10
25 (Figure 2A, Table S1, Figure S1C).
We invited investigators responsible for available collections
with similar phenotypes to participate in the secondary genotyping
phase of the top ranked SNPs (n=41 including proxies,
representing 24 independent signals) from the initial meta-analysis.
Nine independent cohorts contributed 5,873 individuals with
comparable phenotypic inclusion criteria (Table S2). After the
combined meta-analysis of the first and second phase cohorts, the
association of the intronic SNP rs7583877 in AFF3 with ESRD
retained genome-wide significance (odds ratio [OR]=1.29, 95%
confidence interval [CI]: 1.18–1.40, P=1.2610
28; Figure 3A),
with the bulk of the association evidence still provided by the
FinnDiane and UK-ROI cohorts. The population attributable risk
[PAR] for the causal variant underlying the observed association
at rs7583877 was estimated to be 3.5%–10.5%. AFF3 belongs to
the AFF (AF4/FMR2) family and encodes a transcriptional
activator, with DNA-binding activity, initially found to be fused
with MLL in some acute lymphoblastic leukemia patients [7,8].
Recent evidence points to a role for AFF3 as an RNA-binding
protein, with overexpression affecting organization of nuclear
speckles and splice machinery integrity [9]. Variants near AFF3
have been associated with acute lymphoblastic leukemia [10],
rheumatoid arthritis [11,12] and recently T1D [13,14]. Another
locus between the RGMA (RGM domain family, member A) and
MCTP2 (multiple C2 domains, transmembrane 2) genes on
chromosome 15q26 also reached genome-wide significance for
association with ESRD (rs12437854, OR 1.80, 95% CI: 1.48–
2.17, P=2.0610
29; Table 2, Figure 3B). PAR estimates for this
locus varied from 0.5% to 4.1%. For the primary DN phenotype,
an intronic SNP in the ERBB4 gene demonstrated consistent
protective effects in the replication samples and was the top
associated SNP identified from the combined discovery and
second stage analysis; however, this did not reach genome-wide
statistical significance (rs7588550, OR 0.66, 95% CI: 0.56–0.77,
P=2.1610
27, PAR 28.3%–32.5% for removal of the major risk
allele; Table 2, Figure 3C). ERBB4 encodes an epidermal growth
factor receptor subfamily member, and has been implicated in
cardiac, mammary gland and neural development [15,16].
Mutations in ERBB4 have previously been reported in cancer
Figure 1. Flow chart summarizing study design. We applied a two
stage study design, where the top signals from the meta-analysis of
three GENIE studies (UK-ROI, FinnDiane and GoKinD US) were followed
up in phase two analysis, consisting of nine T1D cohorts. After
combined meta-analysis, two signals reached genome-wide signifi-
cance in the analysis of ESRD (P,5610
28). For DN phenotype no loci
reached this threshold, but the strongest association was observed for
ERBB4. These signals were followed up with eQTL studies and functional
analysis. The number of patients (N) refers to the number of samples
after genotype quality control; either the total number of samples or
divided into cases/controls.
doi:10.1371/journal.pgen.1002921.g001
Author Summary
The global prevalence of diabetes has reached epidemic
proportions, constituting a major health care problem
worldwide. Diabetic kidney disease, or diabetic nephrop-
athy (DN)—the major long term microvascular complica-
tion of diabetes—is associated with excess mortality
among patients with type 1 diabetes. Even though DN
has been shown to cluster in families, the underlying
genetic and molecular pathways remain poorly defined.
We have undertaken the largest genome-wide association
study and meta-analysis to date on DN and on its most
severe form of kidney disease, end-stage renal disease
(ESRD). We identified new loci significantly associated with
diabetic ESRD: AFF3 and an intergenic locus on chromo-
some 15q26 residing between RGMA and MCTP2. Our
functional analyses suggest that AFF3 influences renal
tubule fibrosis, a pathological hallmark of severe DN.
Another locus in ERBB4 was suggestively associated with
DN and resides in the same intronic region as a variant
affecting the expression of ERBB4. Subsequent pathway
analysis of the genes co-expressed with ERBB4 indicated
involvement of fibrosis.
GWAS on Diabetic Nephropathy
PLOS Genetics | www.plosgenetics.org 3 September 2012 | Volume 8 | Issue 9 | e1002921[17]. Several studies using Madin-Darby canine kidney (MDCK)
cells and conditional ERBB4 overexpression/knock-out mice,
suggest a crucial role for ERBB4 in renal development and
tubulogenesis [18,19].
It is possible that our observed signal is in linkage disequilibrium
with an untyped SNP, or exerts functional effects over an extended
genomic region. To explore a putative biological signature we
identified, for the top three SNPs, all genes within a 2 Mb window
(1 Mb upstream and downstream). Gene ontology analysis
revealed no significant enrichment of biological terms or pathways
within this subset of flanking genes (Table S3). We determined
whether any of these genes were differentially expressed in
microarray data derived from tubulointerstitial (n=49) or
glomerular (n=70) human early DN renal biopsy material versus
pre-transplant renal biopsies from living kidney donors (n=32)
[20]. Around rs7583877 (AFF3), we noted upregulation of LIPT1
and TXNDC9, while TSGA10 was downregulated in both
tubulointerstitial and glomerular enriched kidney biopsies
(Figure 2 and Table S4). NPAS2, which flanks rs7583877 (AFF3),
and FAM174B and CHD2, which flank rs12437854 (15q26), were
downregulated in glomerular enriched biopsies of DN patients
versus control, but remained unchanged in tubulointerstitial
biopsies (Figure 2 and Table S4). NPAS2 (neuronal PAS domain
protein 2), has been implicated in circadian rhythms in the distal
nephron segments, acting as a regulator of kidney function [21].
Interestingly, mutations in chromodomain helicase DNA binding
protein 2 (CHD2), encoding a chromatin-remodeling enzyme,
result in impaired glomerular function in mice [22]. Furthermore,
at the rs7588550 (ERBB4) locus expression of ERBB4 was down,
and SPAG16 upregulated in tubulointerstitial enriched kidney
biopsy tissue of DN versus control subjects (Figure 2 and Table
S4).
We also examined whether any of the top three SNPs
modulated expression of neighboring genes in cis in a dataset of
glomerular and tubulointerstitial kidney biopsies of Pima Indians
with type 2 diabetes and DN who had been genotyped on the
Affymetrix 6.0 array [23]. In Pima Indians, no adequate proxies
(haplotype-based D9$0.8) for the Affymetrix 6.0 SNPs that were
strongly correlated with GWAS findings (r
2$0.8) could be found
for rs12437854, and expression of AFF3 was below detectable
thresholds in this dataset; however, two SNPs in the same intron of
ERBB4 as rs7588550 (rs17418640 and rs17418814) were associ-
ated with genotype-specific expression of ERBB4 in tubulointer-
stitial but not in glomerular tissue in the Pima cohort (P,0.05;
Figure S2). Follow-up work is required to investigate the DN
associated and eQTL signals in this ERBB4 intron.
To explore the potential functional role of these ERBB4 SNPs,
we looked for other genes whose expression is correlated with that
of ERBB4. A total of 388 ERBB4-correlated genes were found in
the Pima population (Benjamini-Hochberg Q-value,0.1). Path-
way analysis of these genes indicates coexpression of ERBB4 with
collagen-related genes, which have been implicated in renal
fibrosis [24,25] (Genomatix Pathway System; Table S5).
Because the low expression level of AFF3 limited exploration of
this gene using expression data, we pursued additional functional
experiments in an in vitro model of renal fibrosis, namely human
tubular epithelia exposed to transforming growth factor-b1 (TGF-
b1). Low-level basal expression of the AFF3 mouse homologue
(LAF4) has been reported in kidney tubules during embryonic
development [26] suggesting proximal renal tubule epithelial cells
may be suitable for detection and functional interrogation of AFF3.
TGF-b1 is implicated in the development of diabetic glomerulo-
sclerosis, and there is recent appreciation of its role as a key driver
of tubulointerstitial fibrosis. TGF-b1 induces epithelial cell de-
differentiation into a more mesenchymal-like phenotype, charac-
terized by a switch in predominant cadherins from E-cadherin
(epithelial) to N-cadherin (mesenchymal), and increased vimentin,
a-smooth muscle actin, connective tissue growth factor (CTGF)
and Jagged 1 [27,28]. TGF-b1-mediated loss of E-cadherin in
renal epithelia, is believed to be mediated through loss of miR-192
expression [29]. We and others have previously shown that Jagged
1, a ligand for multiple Notch receptors, is up-regulated in human
diabetic kidney disease [30,31], with the Notch signaling pathway
implicated in driving renal fibrosis [32,33]. CTGF is a member of
the CCN protein family, with biological roles in differentiation and
tissue repair. CTGF is induced by TGF-b1 and enhances
expression of multiple extracellular matrix proteins observed in
DN, including collagens and fibronectin, and CTGF expression is
elevated in the glomeruli of STZ (streptozotocin) - treated rats, an
in vivo model of T1D [34]. Basal AFF3 expression was detectable in
HK-2 cells, and expression levels were upregulated upon
stimulation with TGF-b1 (5 ng/ml; 48 h), as measured at protein
and RNA level (Figure 4A–4B). Inhibition of AFF3 by siRNA
attenuated the expression of TGF-b1-driven markers of fibrosis -
CTGF and N-cadherin (Figure 4C–4E). Taken together, these
data suggest that AFF3 may play a role in TGF-b1-induced fibrotic
responses of renal epithelial cells.
Traditionally, DN has been viewed as a continuous trait with
onset at microalbuminuria, progression to macroalbuminuria, loss
of GFR, and culmination in ESRD. Recent studies have called this
paradigm into question, suggesting that the syndrome may
perhaps be composed of varying phenotypes [35,36]. Association
Table 1. Characteristics of samples successfully analyzed in each discovery collection and the meta-analyses.
UK-ROI FinnDiane GoKinD US
Cases
(n=823)
Controls
(n=903)
Cases
(n=1,319)
Micro
(n=460)
Controls
(n=1,591)
Cases
(n=774)
Controls
(n=821)
Gender (M/F) 478/345 395/508 785/534 259/201 656/935 402/372 342/479
Duration of T1D (years) 32.969.6 27.068.6 32.869.1 28.2611.2 27.869.5 31.467.8 25.467.7
Age at diagnosis of T1D (years) 14.567.7 14.5267.8 12.867.6 13.268.2 15.168.3 1166.6 1367.3
HbA1C (%) 9.061.9 8.761.6 8.861.6 8.661.4 8.161.2 7.561.9 7.561.2
BMI (km/m
2)2 6 . 3 64.7 26.264.2 25.564.2 25.963.7 25.263.5 25.765.2 26.164.3
ESRD (%) 29.9 0 48.9 0 0 65.6 0
n=total number of patients; Micro=patients with microalbuminuria; M/F=number of males/females; HbA1C blood glycosylated hemoglobin; BMI=body mass index.
Case=macroalbuminuria or ESRD, Control=normoalbuminuric, see text for full details.
doi:10.1371/journal.pgen.1002921.t001
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different stages of DN was tested on a time-to-event analysis of
relevant endpoints using longitudinal data for participants in the
FinnDiane discovery collection. Consistent with our case-control
GWAS analyses, the strongest association for rs7583877 was
observed for the time from T1D diagnosis to development of
ESRD (hazard ratio [HR] 1.33, 95% CI: 1.18–1.49,
P=1.9610
26), but also the time from T1D diagnosis to
development of macroalbuminuria (HR 1.15, 95% CI: 1.04–
1.27, P=0.006) and the time from macroalbuminuria to ESRD
(HR 1.16, 95% CI: 1.01–1.36, P=0.04) reached nominal
significance. Similarly, rs12437854 was associated with time from
T1D diagnosis to development of macroalbuminuria (HR 1.31,
95% CI: 1.03–1.67, P=0.03) and ESRD (HR 1.35, 95% CI:
1.02–1.77, P=0.03) (Text S1, Table S6, Figure S3). When we
studied these SNPs and their association with various DN-related
phenotypes in the case-control setting of the discovery cohorts,
similar observations were made supporting the role of these SNPs
in the development of ESRD: Whereas we found evidence of
association between rs7583877 (AFF3) and all the examined
phenotypes with ESRD as the case definition, only moderate
association was observed for the DN phenotype (OR=1.14,
P=0.002) and no association when patients with macroalbumin-
uria were compared to controls with normoalbuminuria
(OR=1.00, P=0.95). rs12437854 (RGMA – MCTP2) had the
strongest association with the original ESRD phenotype (controls
defined as all non-ESRD subjects) and with the ESRD vs.
normoalbuminuria phenotype, and moderate association with the
DN phenotype and comparison of ESRD vs. macroalbuminuric
patients (Table S7).
An alternative explanation for our ESRD findings may be that
the associated variants in AFF3 gene and on chromosome 15q26
might be markers of survival. Mortality rates are extremely high
in patients with kidney disease and macroalbuminuria, with at
least 25% of macroalbuminuric patients dying before they reach
ESRD [37]. Thus, the selection of patients with ESRD may be
biased towards selection of severe kidney disease survival. To
address this question, we used the time until death as the final end
point in the longitudinal analysis. Neither of the loci associated
with ESRD was also associated with mortality (Text S1, Table
S6, Figure S3), suggesting that these loci are associated with
ESRD per se.
To explore whether these SNPs contribute to DN via related
intermediate phenotypes, such as adiposity, fasting lipid levels, or
blood pressure we performed in silico searching of publicly
available GWAS datasets for our top SNPs [38–41]. We found
nominal, directionally consistent associations of rs12437854 with
fasting glucose (P=0.03) [42] and of rs7583877 with waist-hip
ratio (P=0.04) [43] (Table S8). We also considered if previously
published T1D and CKD SNP associations were associated with
DN or ESRD in our GWAS meta analyses. Eight of 80 SNPs at
T1D-associated loci showed nominal significance with DN or
ESRD (including three at AFF3 that are in weak LD [r
2 0.030–
0.046 in CEU] with the SNPs described here), while no CKD
SNPs were nominally significant (Table S9) [44–47]. The lack of
association with DN for CKD-associated SNPs suggests that the
genetic risk factors for DN may differ from the genetic risk factors
for CKD in a nondiabetic population.
Finally, to generate further biological hypotheses based on our
GWAS results, we employed MAGENTA [48] gene set enrich-
ment analysis software integrating Gene Ontology (GO) terms,
KEGG and Ingenuity pathways and PANTHER database entries
(Table S10). In the analysis of DN as a case phenotype, enriched
gene sets included ‘‘sugar binding’’ (P=0.0006), ‘‘double stranded
DNA binding’’ (P=0.001) and ‘‘nucleic acid binding’’ (P=0.004).
In the analysis of ESRD significantly enriched gene sets (P,0.01)
included an enrichment of terms associated with DNA binding,
including ‘‘sequence-specific DNA binding’’ (P=0.003), ‘‘positive
Figure 2. Regional association plots for top ranked SNPs with associated gene expression data. Panels represent independent signals for
the primary DN and ESRD analysis. The color of the SNP symbol indicates the linkage disequilibrium (r
2) with the index SNP which is colored purple.
Blue and red gene colors in the lower part of each figure panel indicate up and down regulation in tubulointerstitial or glomerular DN kidney
biopsies, respectively. Genes with no change in expression are indicated with black; no data on gene expression with gray color. (A) Association of
rs7583877 with ESRD. (B) Association of rs12437854 with ESRD. (C) Association of rs7588550 with DN.
doi:10.1371/journal.pgen.1002921.g002
Figure 3. Forest plots for significant hits incorporating discovery and replication plots. Plots show the study-specific association
estimates (OR) and 95% confidence intervals for the discovery and second phase studies. (A) Association of rs7583877 with ESRD; heterogeneity
P=0.037. (B) Association of rs12437854 with ESRD; heterogeneity P=0.046. (C) Association of rs7588550 with DN; heterogeneity P=0.467. The
association estimate and confidence interval for the meta-analysis combining the discovery and second-stage results are denoted by the diamond.
doi:10.1371/journal.pgen.1002921.g003
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scription factor’’ (P=0.004). Taken together, the principal
biological signal found within GWAS data suggests an enrichment
of transcriptional regulators.
In this largest meta-analysis to date of DN from individuals with
T1D, we found two genome-wide significant associations with
ESRD. Variants in AFF3 have been shown to be associated with
juvenile idiopathic rheumatoid arthritis, Graves’ disease, celiac
disease and T1D, indicating this may be a pan-autoimmune
disease gene. It is possible that the AFF3 signal represents an
association with T1D and/or is a false positive finding, as it was
not seen in the follow-up cohorts. However, we note the following:
1) both FinnDiane and UK-ROI yielded very similar association
results, 2) the number of ESRD cases in the replication cohorts is
small (n=363), indicating that statistical power to replicate the
original association is limiting, 3) the association result in the
second stage, while non-significant, trends in a consistent direction
(OR 1.11), 4) after evaluating .12,000 individuals the AFF3 signal
remained genome-wide significant (P=1.2610
28), and 5) we have
provided supportive functional evidence that suggests AFF3 may
be a relevant contributor to renal disease. Although survival bias is
a possibility in the analyses of ESRD, longitudinal analysis
revealed the association of the AFF3 and chromosome 15q26 loci
with renal end-points and not with death. Experimental models
provide independent evidence of AFF3 involvement in renal
fibrosis and support an association of this locus with a renal
Table 2. Results from discovery, second stage, and combined meta-analysis for supported markers.
Discovery Stage 2 Combined
SNP Phenotype A1 A2
Freq
(A1) Region OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value
rs12437854 ESRD G T 0.038 15q26 (RGMA-MCTP2) 1.72 (1.36–2.18) 7.6610
26 1.95 (1.41–2.7) 5.4610
25 1.80 (1.48–2.17) 2.0610
29
rs7583877 ESRD C T 0.289 2q11.2-q12 (AFF3) 1.34 (1.22–1.48) 4.8610
29 1.11 (0.93–1.34) 0.25 1.29 (1.18–1.40) 1.2610
28
rs7588550 T1DN G A 0.052 2q33.3-q34 (ERBB4) 0.65 (0.55–0.79) 5.3610
26 0.67 (0.49–0.92) 0.01 0.66 (0.56–0.77) 2.1610
27
A1=minor allele=effect allele; A2=major allele; Freq(A1)=minor allele frequency; OR=odds ratio; 95% CI=95% confidence interval. Discovery: Meta analysis results
for GENIE discovery cohorts. Stage 2: Meta analysis results for replication cohorts. Combined: Meta analysis results for discovery and the stage 2 cohorts. NA=no result,
due to genotype failure or quality control filtering.
doi:10.1371/journal.pgen.1002921.t002
Figure 4. AFF3 is upregulated in renal epithelial cells (HK-2) stimulated with pro-fibrotic TGF-b1. (A) Western blot of AFF3 protein
expression in HK-2 cells stimulated with TGF-b1 (5 ng/ml; 24–48 h). (B) TaqMan quantitative PCR analysis of AFF3 mRNA expression in HK-2 cells
stimulated with TGF-b1 (5 ng/ml; 48 h) and (C) AFF3 mRNA expression in HK-2 cells transfected with AFF3 siRNA in the presence (black bar)/absence
(grey bar) of TGF-b1 (5 ng/ml; 48 h). (D) TaqMan quantitative PCR analysis of N-cadherin, CTGF, Jagged1 and E-cadherin expression in HK-2 cells
transfected with AFF3 siRNA in the presence (black bar)/absence (grey bar) of TGF-b1 (5 ng/ml; 48 h). (E) Representative Western blot of N-cadherin,
CTGF, Jagged1 and E-cadherin protein responses in HK-2 cells transfected with AFF3 siRNA in the presence/absence of TGF-b1 (5 ng/ml; 48 h). HK-2
cells transfected with control siRNA were selected as a control. For TaqMan PCR, expression was normalized to GAPDH. Data are plotted as mean 6
SE (n=3; *P,0.05, **P,0.01).
doi:10.1371/journal.pgen.1002921.g004
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achieve genome-wide statistical significance for DN using a
combined proteinuria/ESRD phenotype, suggesting that this
phenotype may have been too heterogeneous to detect significant
associations with a sample of this size. For example, lifelong
glycemic control, a known risk factor for DN, is not well captured
in most existing cohorts. Nevertheless, this study is the largest, well
powered GWAS on DN to date. We demonstrated a suggestive
signal of association at ERBB4 that is supported by experimental
data showing haplotype specific mRNA expression in DN biopsies.
Our findings reinforce the need for additional studies of patients
with T1D and a homogeneous renal phenotype, in whom
additional GWAS, fine-mapping and sequencing to uncover rare
variants could be performed. Integration of our findings with
ongoing GWAS in both type 1 and type 2 diabetes DN may also
lead to discovery of additional genetic determinants of DN. The
traditional phenotypic definition of DN for individuals with type 2
diabetes may be even more challenging for genetic studies given
the heterogeneity of vascular complications and differential renal
diagnoses. Several larger-scale GWAS have now been conducted
for renal phenotypes [49–56], however in most cases the true
disease-causing variant and functional impact for specific pheno-
types remains to be established. Encouraging reports include the
association of uromodulin with CKD [57], MYH9/APOL1 with
non-diabetic ESRD [58,59], and PLA2R1 with membranous
nephropathy, where anti-PLA2R antibodies appear to predict
activity of the disease as well as response to therapy [60].
Our findings point to two transcriptional networks centered
around AFF3 and ERBB4 that may be operational in the
pathogenesis of kidney disease in diabetes.
Methods
Ethics statement
All human research was approved by the relevant institutional
review boards, and conducted according to the Declaration of
Helsinki.
Study populations
We implemented a two stage analysis, in which a GWAS was
performed using a set of three discovery cohorts in the GENIE
consortium, and top signals for the DN and ESRD analyses were
analyzed further in the second phase in a set of nine independent
cohorts (described below) with 5,873 patients in total. The patient
numbers in the individual studies are given in Table S11.
Additional details are provided in the online material Text S1.
All Ireland, Warren 3, Genetics of Kidneys in Diabetes UK
(UK-ROI) Collection [61]
Inclusion criteria included white individuals with T1D, diag-
nosed before 31 years of age, whose parents and grandparents
were born in the UK and Ireland. The case group comprised 903
individuals with persistent proteinuria (.500 mg/24 h) develop-
ing more than 10 years after the diagnosis of diabetes,
hypertension (.135/85 mmHg and/or treatment with antihyper-
tensive medication), and retinopathy; ESRD (27.2%) was defined
as individuals requiring renal replacement therapy or having
received a kidney transplant. Absence of DN was defined as
persistent normal urine albumin excretion rate (AER; 2 out of 3
urine albumin to creatinine ratio [ACR] measurements ,20 mgo f
albumin/mg of creatinine) despite duration of T1D for at least 15
years, while not taking an antihypertensive medication, and having
no history of treatment with ACE inhibitors; 1,001 individuals
formed the control group. After exclusion of patients with low
quality DNA samples, 914 DN/ESRD cases and 956 controls
remained for the GWAS.
Finnish Diabetic Nephropathy Study (FinnDiane) [62]
The FinnDiane study is a Finnish cohort of more than 4,800
adult ethnic Finns with T1D, recruited from across Finland,
diagnosed prior to age 35 and insulin treatment begun within 1
year. This study comprises 1,721 patients with normal AER, 516
with microalbuminuria, 733 with macroalbuminuria and 682 with
ESRD. The disease status was defined by urine AER or urine
ACR in at least two out of three consecutive urine collections at
local centers: Microalbuminuria was defined as AER$20,200 -
mg min
21 or $30,300 mg/24 h or an ACR of 2.5–
25 mg mmol
21 for men and 3.5–35 mg mmol
21 for women in
overnight, 24-hour or spot urine collections, respectively. Similar-
ly, the limit for macroalbuminuria was AER$200 mg min
21 or
$300 mg/24 h or ACR$25 mg mmol
21 for men and
$35 mg mmol
21 for women. ESRD was defined as ongoing
dialysis treatment or transplanted kidney. Control patients with
normal AER were required to have T1D duration of at least 15
years. 558 of these patients were included from an independent
Finnish cohort collected by the National Institute of Health and
Welfare. These patients met the FinnDiane diagnosis and selection
criteria, and were analyzed together with the FinnDiane cohort.
Genetics of Kidneys in Diabetes US Study (GoKinD US)
[63]
The GoKinD US study consists of a DN case-control cohort of
individuals diagnosed with T1D prior to 31 years of age who
began insulin treatment within 1 year of T1D diagnosis. Controls
were 18–59 years of age, with T1D for at least 15 years but
without DN, n=889. DN definition includes individuals with
ESRD, dialysis or kidney transplant and persistent macroalbu-
minuria (at least 2 out of 3 tests positive for albuminuria by
dipstick $1+, or ACR.300 mg albumin/mg of urine creatinine).
Cases were defined as people 18–54 years of age, with T1D for at
least 10 years and DN, n=903. Individuals recruited to the
control group employed the same inclusion criteria as UK-ROI.
Individuals were recruited at two study centers, George Washing-
ton University (GWU) and the Joslin Diabetes Centre (JDC) using
differing methods of ascertainment and recruitment [64]. Analysis
of the GoKinD US cohort was limited to individuals whose
primary ethnicity was Caucasian.
Collections genotyped in Phase 2
DNA was sought from worldwide case-control collections of
individuals with T1D and known renal status. A total of 5,873
individuals from nine independent collections were genotyped or
imputed for the top-ranked SNPs (n=41 including 17 proxies),
with the exception of the DCCT/EDIC cohort where GWAS data
was imputed. All the patients included in the phase two analysis
were adults of European descent and had T1D diagnosed before
35 years of age. Controls with normal AER had duration of T1D
at least 15 years, and cases with DN had minimum T1D duration
of 10 years. If a collection included patients with microalbumin-
uria, they were excluded from the primary analysis of DN, but
included as controls in the analysis of ESRD versus non-ESRD.
The main clinical characteristics of all the replication cohorts are
shown in the Table S2 and the cohorts are described in Text S1.
Phenotype definitions
The primary phenotype of interest was DN, defined as
individuals aged over 18, with T1D for at least 10 years and
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macroalbuminuria as defined in the cohort descriptions above.
Controls were defined as individuals with T1D for at least 15 years
but without any clinical evidence of kidney disease. Individuals
with microalbuminuria were excluded from the primary DN
analysis in all cohorts. Disease status definitions were consistent
across all the study cohorts. Details of clinical characteristics for
each cohort are defined in Table 1 and Table S2. We evaluated a
second phenotype to gain further insights into the genetic basis of
the most severe form of DN (leading to ESRD), and compared
ESRD cases to all those without ESRD. This phenotype is referred
to as the ‘‘ESRD’’ or ‘‘ESRD vs. non-ESRD’’ phenotype
throughout the manuscript. We also considered individuals with
ESRD compared to T1D controls with no clinical evidence of DN.
Results for this comparison are given in the online supporting
material (Tables S1, S6, S7, S9, S10), where this contrast is called
‘‘ESRD vs. normoalbuminuria’’ or ‘‘ESRD vs. normo’’.
Genotyping
DNA from individuals in the UK-ROI collection were
genotyped using the Omni1-Quad array (Illumina, San Diego,
CA, USA) while FinnDiane samples employed Illumina’s
BeadArray 610-Quad array. Samples in UK-ROI and FinnDiane
were excluded if they had insufficient DNA quality, quantity or
poor genotype concordance with previous genotypes during the
fingerprint evaluation stage. Existing genotype data for the
GoKinD US genotype data was downloaded from dbGAP
(phs000018.v2.p1, retrieved June 2010), containing updated
genotype data from Affymetrix 500 K set (Affymetrix, Santa
Clara, CA, USA).
Genotype quality control
Samples for UK-ROI and FinnDiane were excluded for
insufficient DNA quality, quantity or poor genotype concordance
with previous genotypes during a fingerprint evaluation stage. In the
UK-ROI sample, 1,830 unique case (n=872) and control (n=958)
individuals were submitted for genotyping on the Omni1-Quad. For
FinnDiane, 3,651 individuals (cases, n=1,934; controls n=1,721)
were submitted for genotyping on the 610-Quad. For all three
discovery datasets (UK-ROI, FinnDiane, GoKinD US), uniform and
extensive genotype quality control procedures were applied: SNPs
were filtered for those with call rates greater than 90%, minor allele
frequency (MAF) exceeding 1%, and concordance with Hardy
Weinberg Equilibrium (HWE, P,10
27). Sample filters included
individual call rates greater than 95%, no extreme heterozygosity and
cryptic relatedness as determined using identity by descent (first
degree relatives, estimated identity by descent .0.4), and admixture
assessment using principal components (plotted with HapMap
reference panel, Figure S4). Additional quality control measures
included test of missing by haplotype (P,10
28), missing by
phenotype (P.10
28) and plate effects (P,10
27). These quality
control steps were performed using PLINK [65] with custom Perl
and R analysis scripts. Known copy number variation and
mitochondrial SNPs were excluded from analyses. Detailed results
of each QC step are reported in Table S12 for each study population.
A HapMap control sample was included on all genotyping
plates for UK-ROI; average call rate was 99.9% with HapMap
concordance equaling 99.7%. The average sample call rate was
99.5% in UK-ROI with sample heterozygosity 22.1%. Concor-
dance with internal control for FinnDiane was 99.996% with an
average sample call rate of 99.8%.
Principal Component Analysis (PCA) was performed separately
for each of the three studies with the EIGENSTRAT program
[66] in order to detect genetic outliers and to adjust the analyses
for population structure. Genetic outliers were defined as more
than six standard deviations away from the center of distribution
along any of the ten first principal components and the procedure
was repeated until no outliers were detected. After filtering, PCA
were calculated for each study cohort combined with unrelated
individuals from three original HapMap populations (www.
hapmap.org), and plotted to identify additional admixed individ-
uals. The first ten principal components were employed to adjust
the association analysis for any residual population structure from
the cleaned datasets.
In total, directly genotyped results for 823 cases and 903
controls in 791,687 SNPs passed QC procedure in UK-ROI.
Similarly, 549,530 SNPs with average genotyping rate of 99.9%
passed the QC filters in 1,319 cases, 1,591 controls and 460
individuals with microalbuminuria for FinnDiane. 360,899 SNPs
in 774 cases and 821 controls for GoKinD US passed quality
control and were included in the analysis.
Imputation
Imputation was performed after the quality control employing
MACH 1.0 software (http://www.sph.umich.edu/csg/abecasis/
MACH) with HapMap phase II CEU population as a reference,
resulting in ,2.4 million SNPs for each cohort. The cross-over
and error rates were estimated with 50 iteration rounds in roughly
300 randomly selected samples. The imputation was run with the
greedy algorithm and the maximum likelihood method in order to
obtain expected allele dosages rather than integer allele counts.
SNPs with low imputation quality (r
2,0.6) are not reported.
Statistical analysis
PLINK v1.07 [67] was employed to conduct association tests for
the allele dosage data with logistic regression adjusted for sex, age,
the duration of diabetes and the ten first components of the study
specific principal component analysis. UK-ROI and GoKinD US
were adjusted for study center, but in the primary DN phenotype
the two GoKinD US centers; GWU and JDC, were analyzed
separately. Results from individual studies were adjusted for study
specific genomic inflation factor and then combined by fixed effect
meta-analysis model using METAL [68], to estimate the combined
effect sizes and significances from beta values and standard error.
Regional association plots were generated using hg18 in Locus-
Zoom [69]. Quantile-Quantile plots were generated to evaluate the
number and magnitude of observed associations compared with
those expected under the null hypothesis (Figure S1).
Second-phase SNP selection and genotyping
All SNPs observed with P,10
25 were selected for further
analysis. These SNPs were reviewed and a top SNP (with a proxy)
was selected for each independent signal (SNPs more than 500 kb
distant or LD r
2,0.3 in HapMap II CEU) using the LD-based
clumping procedure implemented in PLINK. De novo genotyping
was performed for all phase two cohorts except for DCCT/EDIC
using identical designs of Sequenom IPLEX assays (Sequenom
Inc, San Diego, US). The DCCT/EDIC samples were imputed
from their GWAS results that had undergone their respective
quality control procedure. The statistical analysis was similar to
the discovery cohorts with the difference that the models were not
adjusted for principal components. All results were then combined
by meta-analysis using METAL software as previously described.
Longitudinal analysis
Time to event analyses were performed on longitudinal data
from the FinnDiane discovery cohort using Kaplan-Meier and
GWAS on Diabetic Nephropathy
PLOS Genetics | www.plosgenetics.org 9 September 2012 | Volume 8 | Issue 9 | e1002921Cox proportional hazards regression with the aim to evaluate the
genetic association of rs7583877 and rs12437854 with time from
the diagnosis of T1D to the onset of the following end points:
microalbuminuria, macroalbuminuria or ESRD. Additionally, we
analyzed time from onset of macroalbuminuria to development of
ESRD. The most recent kidney status data were utilized for each
patient. We also examined if the two main association loci,
rs7583877 and rs12437854, were associated with mortality using
data from the Finnish Death Registry (as per 30.9.2010). As DN
(defined as macroalbuminuria or ESRD) is strongly associated
with mortality, the time to death was separately analyzed for
patients without DN (time from T1D onset to death; patients who
developed DN were censored at the time of the onset of DN) and
for those with DN (time from onset of DN to death and time from
onset of ESRD to death). Analyses were performed using the
‘survival’ package in R software (version 2.36-10, http://cran.r-
project.org/web/packages/survival). (See Text S1.)
Additional analyses
SNPs were annotated with associated genes and function using
dbSNP build 132, human build 37.1. Cytogenetic locations for
genes were sourced from Entrez gene; locations for SNPs that were
not associated with genes were recorded from NCBI MapView. In
silico analyses included gene set enrichment using MAGENTA
[48]. To explore functional implications of AFF3, human kidney
epithelial cells (HK-2) were cultured and evaluated (Figure 4).
Renal biopsy populations
Gene expression was measured in renal tissue compartments
micro-dissected from renal biopsies from Pima Indians with type 2
diabetes and early stage DN (n=77), as well as from Caucasian
living kidney transplant donors (n=20). Pima Indian subjects are
25–68 in age, with measured ACR in the range 5.23–7162, and
GFR in the range 40.45–274.80.
Renal expression
Renal biopsies were micro-dissected into glomeruli and either
tubulointerstitial or cortical compartments, and gene expression
measured using the Affymetrix HGU-133A and HGU-133 Plus 2
platforms [70]. Background adjustment, quantile normalization
and probe-set summarization were performed with in a Gene-
Pattern (www.genepattern.org) pipeline using Robust Multichip
Analysis [71] with batch correction using Combat [72]. The
differential expression data sets were processed with the Entrez
Gene Custom CDF v.10, and the eQTL data sets were processed
with the RefSeq Custom CDF v.12 [73] for probe-sets common to
both expression platforms.
eQTL association
The Affymetrix 6.0 genotyping platform was used to genotype
Pima Indians with glomerular expression (n=65), a subset of which
(n=54) also had tubulointerstitial/cortical expression. The cis region
of each gene was defined as 150 kb upstream of the transcript start
site and 50 kb downstream of the transcription end site.
Supporting Information
Figure S1 Manhattan and QQ-plots for DN and ESRD
phenotypes. Manhattan plots (panels A and C) highlighting P
values from the discovery meta-analysis where dotted horizontal
lines represent the threshold for follow up, P,1610
25, and the
solid horizontal lines indicate the threshold for genome-wide
significance, P,5610
28. The nearest genes are indicated above
regions of interest. SNPs that reached threshold P,1610
25 and
were selected for follow up are denoted as black diamonds, SNPs
in linkage disequilibrium (R.0.6) with top SNP are denoted with
blue dots, and final meta analysis P values (discovery+phase 2
results) as red triangles. Q-Q plots (panels B and D) evaluated
inflation of the GWAS results and show the expected versus
observed P values; the diagonal line is the line of identity. The
inflation factor l for the genomic control is indicated in the Q-Q
plots.
(TIF)
Figure S2 Box and whisker plots of normalized ERBB4
expression intensities in glomerulus (A,B) and tubulointerstitium
(C,D) by genotype showing eQTL associations in tubulointersti-
tium. Both SNPs show significant eQTL associations in tubulo-
interstitial kidney biopsies of Pima Indians with type 2 diabetes
and DN (P=0.018 for rs1718640, P=0.024 for rs17418814;
linear regression using additive model). Association remained
significant for rs17418640 when the subject with homozygous
minor allele was excluded (P=0.043). Associations with glomer-
ular expression are not significant. Gene expression in kidneys was
evaluated with Affy HGU-133A custom CDF probesets annotated
to RefSeq transcripts NM_005235 and NM_001042599, and
SNPs were genotyped with Affy 6.0 genotyping platform.
Conditional analysis indicates rs17418814 is dependent on
rs1718640 (P=0.95 conditioned on rs1718640, versus rs1718640
P=0.48 conditioned on rs17418814). Both SNPs lie within the
same intron of the ERBB4 gene as rs7588550 that was suggestively
associated with DN.
(TIF)
Figure S3 Longitudinal analyses in FinnDiane for rs7583877
(AFF3) and rs12437854 (chromosome 15q26). Analyses assume an
additive model of the SNP effects. The plotted survival curves have
been truncated at the point at which fewer than five participants
remained with the corresponding genotype. The genotype legend
in each figure indicates the number of samples with the
corresponding genotype, shown in parentheses. The P-value is
indicated for the nominally significant associations (P,0.05).
ns=not significant. The bottom part of each figure indicates the
number of samples at risk at ten-year intervals.
(TIF)
Figure S4 Rooted Principal Component Analysis of the
discovery cohorts. Two first principal components (PC1 and
PC2) are shown for (A) UK-ROI, (B) FinnDiane and (C) GoKinD
US. Principal Component Analysis was calculated with EIGEN-
STRAT software including CEU, YRI and CBT from HapMap II
as reference samples.
(TIF)
Table S1 Top ranked SNPs selected for DN, ESRD vs. non
ESRD, and ESRD vs. normoalbuminuria phenotypes.
(DOC)
Table S2 Clinical characteristics and information on genotyping
of the phase two cohorts.
(XLS)
Table S3 Gene ontology analysis of all genes within 61 Mbp of
top GWAS signals: rs7583877/AFF3; rs12437854/15q26;
rs7588550/ERBB4.
(DOC)
Table S4 Gene expression in early DN versus living donor
kidney biopsies. All genes within a 2 Mb window (1 Mb upstream
and downstream) of the three main signals (rs7583877/AFF3,
rs12437854/15q26, rs7588550/ERBB4) were studied.
(DOC)
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System) for the ERBB4-correlated genes in early diabetic
nephropathy.
(DOC)
Table S6 Cross-sectional and longitudinal analyses in Finn-
Diane for rs7583877 (AFF3) and rs12437854 (chromosome
15q26).
(DOC)
Table S7 Additional kidney phenotype analysis results for the
three main loci.
(DOC)
Table S8 P-value for association with DN related traits for the
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